Randomized double-blind placebo-controlled trial of bestatin in patients with resected state I squamous-cell lung carcinoma

Journal of the National Cancer Institute

Volumn 95, Issue 8, 2003, Pages 605-610

  Ichinose, Yukito ^a   Genka, Keiichiro ^b   Koike, Teruaki ^c   Kato, Harubumi ^d   Watanabe, Yoh ^e   Mori, Takashi ^f   Iioka, Sogo ^g   Sakuma, Akira ^h   Ohta, Mitsuo ^a   Kawamura, M ⁱ   Yokoi, K ^j   Sakuma, T ^k   Tsubota, N ^l   Yoshimura, M ^l   Yanai, N ^m   Nagasaka, F ⁿ   Nakagawa, K ^o   Tojo, T ^p   Sato, T ^q   Ohta, S ^r   Yamaoka, N ^s   Matsuzaki, Y ^t   Fujimura, S ^u   Nagai, K ^v   Miyamoto, H ^w   Kobayashi, K ^x   Saito, H ^y   Isobe, J ^z   Yasumitsu, T ^aa   Doi, O ^ab   Kuwahara, O ^ac   Hatta, T ^ad   Katakami, N ^ae   Maebeya, S ^af   Shimizu, N ^ag   Nakagawa, J ^ah   Motohiro, A ^ai   Hirata, T ^aj   more..

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b National Hospital Organization Okinawa National Hospital   (Japan)

^c NIIGATA CANCER CENTER HOSPITAL   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

^f Natl Kinki Chuo Hosp Chest Dis   (Japan)

^g OSAKA CITY GENERAL HOSPITAL   (Japan)

^h Tokyo Medical/Dental University ^*  (Japan)

ⁱ Nakadori Hospital   (Japan)

^j TOCHIGI CANCER CENTER   (Japan)

^k Sendai Kohsei Hospital   (Japan)

^l HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^m National Seiransou Hospital   (Japan)

ⁿ NIHON UNIVERSITY   (Japan)

^o CANCER INSTITUTE HOSPITAL   (Japan)

^p NARA MEDICAL UNIVERSITY   (Japan)

^q Yamagata Prefectural Central Hospital   (Japan)

^r SHIZUOKA GENERAL HOSPITAL   (Japan)

^s OITA PREFECTURAL HOSPITAL   (Japan)

^t UNIVERSITY OF MIYAZAKI   (Japan)

^u TOHOKU UNIVERSITY   (Japan)

^v NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^w MITSUI MEMORIAL HOSPITAL   (Japan)

^x KEIO UNIVERSITY   (Japan)

^y Kouseiren Takaoka Hospital   (Japan)

^z National Hospital Organization   (Japan)

^aa OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^ab OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^ac TONEYAMA NATIONAL HOSPITAL   (Japan)

^ad HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

^ae KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^af WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^ag OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^ah KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^ai FUKUOKA NATIONAL HOSPITAL   (Japan)

^aj ASAHIKAWA MEDICAL COLLEGE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; ASPARTATE AMINOTRANSFERASE; BESTATIN; CREATININE; ENZYME INHIBITOR; PLACEBO;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSTIMULATION; KAPLAN MEIER METHOD; LEUKOPENIA; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; STATISTICAL ANALYSIS; THROMBOCYTOPENIA;

EID: 0038364080     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.8.605     Document Type: Article

References (43)

1. Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot 1976;29:97-9.
2. Ishizuka M, Saito K, Sugiyama Y, Takeuchi T, Umezawa H. Mitogenic effect of bestatin on lymphocytes. J Antibiot 1980;33:653-62.
3. Leyhausen G, Schuster DK, Vaith P, Zahn RK, Umezawa H, Falke D, et al. Identification and properties of the cell membrane bound leucine aminopeptidase interacting with the potential immunostimulant and chemotherapeutic agent bestatin. Biochem Pharmacol 1983;32:1051-7.
4. Müller WE, Schuster DK, Zahn RK, Maidhof A, Leyhausen G, Falke D, et al. Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells. Int J Immunopharmacol 1982; 4:393-400.
5. Look AT, Ashmun RA, Shapiro LH, Peiper SC. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 1989;83:1299-307.
6. Ashmun RA, Look AT. Metalloprotease activity of CD13/aminopeptidase N on the surface of human myeloid cells. Blood 1990;75:462-9.
7. Taylar A. Aminopeptidase: structure and function. FASEB J 1993;7:290-8.
8. Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 1993;82:1052-70.
9. Razak K, Newland AC. The significance of aminopeptidase and haematopoietic cell differentiation. Blood Rev 1992;6:243-50.
10. Burley SK, David PR, Lipscomb WN. Leucine aminopeptidase: bestatin inhibition and a model for enzyme-catalyzed peptide hydrolysis. Proc Natl Acad Sci U S A 1991;88:6916-20.
11. Riemann D, Kehlen A, Langner J. CD13--not just a marker in leukemia typing. Immunol Today 1999;20:83-8.
12. Saiki I, Fujii H, Yoneda J, Abe F, Nakajima M, Tsuruo T, et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 1993;54:137-43.
13. Fujii H, Nakajima M, Aoyagi T, Tsuruo T. Inhibition of tumor cell invasion and matrix degradation by aminopeptidase inhibitor. Biol Pharm Bull 1996; 19:6-10.
14. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-7.
15. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 2001;97:652-9.
16. Ezawa K, Minota K, Dobashi K. Induction of apoptosis by ubenimex (Bestatin) in human non-small-cell lung cancer cell lines. Biomed Pharmacother 1996;50:283-9.
17. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002;122:376-86.
18. Abe F, Shibuya K, Uchida M, Takahashi K, Horinishi H, Matsuda A, et al. Effect of bestatin on syngeneic tumors in mice. Gann 1984;75:89-94.
19. Talmadge JE, Lenz BF, Pennington R, Long C, Phillips H, Schneider M, et al. Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res 1986;46:4505-10.
20. Ino K, Goto S, Nomura S, Isobe K, Nawa A, Okamoto T, et al. Aminopeptidase inhibitor ubenimex inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity. Anticancer Res 1995; 15:2081-7.
21. Ohta K, Kurita S, Yamada K, Masaoka T, Uzuka Y, Ogawa N. Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol Immunother 1986;23:5-10.
22. Urabe A, Mutoh Y, Mizoguchi H, Takaku F, Ogawa N. Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Ann Hematol 1993; 67:63-6.
23. Ino K, Bierman PJ, Varney ML, Heimann DG, Kuszynski CA, Walker SA, et al. Monocyte activation by an oral immunomodulator bestatin in lymhoma patients following autologous bone marrow transplantation. Cancer Immunol Immunother 1996;43:206-12.
24. Yasumitsu T, Ohshima S, Nakano N, Kotake Y, Tominaga S. Bestatin in resected lung cancer a randomized clinical trial. Acta Oncologica 1990;29: 827-31.
25. Mountain CF. A new international staging system for lung cancer. Chest 1986;89(4 Suppl):225S-233S.
26. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
27. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48. 1979:14-21.
28. Lachin JM. Introduction to sample size determination and power analysis for clinical trial. Control Clin Trials 1981;2:93-113.
29. Cox DR. Regression models and life-tables. J Roy Statist Soc Ser B 1972; 34:187-220.
30. Williams DE, Pairolero PC, Davis CS, Bernatz PE, Payne WS, Taylor WF, et al. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 1981;82:70-6.
31. Tartter PI, Burrows L, Kirschner P. Perioperative blood transfusion adversely affects prognosis after resection of stage I (subset N0) non-oat cell lung cancer. J Thorac Cardiovasc Surg 1984;88:659-62.
32. Gail MH. A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. Chest 1994;106:287S-92S.
33. McKneally MF, Maver CM, Kausel HW. Regional immunotherapy of lung cancer with intrapleural BCG. Lancet 1976;1:377-9.
34. Ichinose Y, Hara N, Ohta M, Yano T, Maeda K, Asoh H, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer? J Thorac Cardiovasc Surg 1993;106: 90-4.
35. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9.
36. Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Yokose T, et al. Conventional clinicopathologic prognoses factors in surgically resected nonsmall cell lung carcinoma. Cancer 1999;86:1976-84.
37. Thomas P, Rubinstein LV. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Ann Thorac Surg 1990;49:242-7.
38. Hadden JW, Renoux G, Chrigos M. The characterization of immunotherapeutic agents. Immunopharmacol Rev 1990;1:1-64.
39. Sekine K, Fujii H, Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia 1999;13:729-34.
40. Dong X, An B, Salvucci Kierstead L, Storkus WJ, Amoscato AA, Salter RD. Modification of the amino terminus of a class II epitope confers degradation by CD13 on dendritic cells and enhances presentation to T cells. J Immunol 2000;164:129-35.
41. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605-18.
42. Bruley-Rosset M, Florentin I, Kiger N, Schulz J, Mathé G. Restoration of impaired immune function of aged animals by chronic bestatin treatment. Immunology 1979;38:75-83.
43. Ebihara K, Abe F, Yamashita T, Shibuya K, Hayashi E, Takahashi K, et al. The effect of ubenimex of N-methyl-N′-nitro-N-nitrosoguanidine-induced stomach tumor in rats. J Antibiot (Tokyo) 1986;39:966-70.